Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

807 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines.
García-Molina P, Sola-Leyva A, Luque-Navarro PM, Laso A, Ríos-Marco P, Ríos A, Lanari D, Torretta A, Parisini E, López-Cara LC, Marco C, Carrasco-Jiménez MP. García-Molina P, et al. Among authors: marco c. Pharmaceutics. 2022 Feb 16;14(2):426. doi: 10.3390/pharmaceutics14020426. Pharmaceutics. 2022. PMID: 35214160 Free PMC article.
Anticancer and Structure Activity Relationship of Non-Symmetrical Choline Kinase Inhibitors.
Schiaffino-Ortega S, Mariotto E, Luque-Navarro PM, Kimatrai-Salvador M, Rios-Marco P, Hurtado-Guerrero R, Marco C, Carrasco-Jimenez MP, Viola G, López-Cara LC. Schiaffino-Ortega S, et al. Among authors: marco c. Pharmaceutics. 2021 Aug 29;13(9):1360. doi: 10.3390/pharmaceutics13091360. Pharmaceutics. 2021. PMID: 34575436 Free PMC article.
Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors.
Luque-Navarro PM, Mariotto E, Ballarotto M, Rubbini G, Aguilar-Troyano FJ, Fasiolo A, Torretta A, Parisini E, Macchiarulo A, Laso A, Marco C, Viola G, Carrasco-Jimenez MP, López-Cara LC. Luque-Navarro PM, et al. Among authors: marco c. Pharmaceutics. 2022 Mar 27;14(4):715. doi: 10.3390/pharmaceutics14040715. Pharmaceutics. 2022. PMID: 35456549 Free PMC article.
New non-symmetrical choline kinase inhibitors.
Schiaffino-Ortega S, López-Cara LC, Ríos-Marco P, Carrasco-Jimenez MP, Gallo MA, Espinosa A, Marco C, Entrena A. Schiaffino-Ortega S, et al. Among authors: marco c. Bioorg Med Chem. 2013 Nov 15;21(22):7146-54. doi: 10.1016/j.bmc.2013.09.003. Epub 2013 Sep 11. Bioorg Med Chem. 2013. PMID: 24080101
Lead optimization-hit expansion of new asymmetrical pyridinium/quinolinium compounds as choline kinase α1 inhibitors.
Rubbini G, Buades-Martín AB, Kimatrai-Salvador M, Entrena A, Gallo-Mezo MÁ, Ríos-Marco P, Marco C, Mattiuzzo E, Bortolozzi R, Mariotto E, Greco FA, Macchiarulo A, Carrasco-Jiménez MP, Viola G, López-Cara LC. Rubbini G, et al. Among authors: marco c. Future Med Chem. 2018 Aug 1;10(15):1769-1786. doi: 10.4155/fmc-2018-0059. Epub 2018 Jul 25. Future Med Chem. 2018. PMID: 30043647
Choline kinase active site provides features for designing versatile inhibitors.
Serran-Aguilera L, Nuti R, López-Cara LC, Ríos-Marco P, Carrasco MP, Marco C, Entrena A, Macchiarulo A, Hurtado-Guerrero R. Serran-Aguilera L, et al. Among authors: marco c. Curr Top Med Chem. 2014;14(23):2684-93. doi: 10.2174/1568026614666141216093337. Curr Top Med Chem. 2014. PMID: 25515750
Antitumoral alkylphospholipids alter cell lipid metabolism.
Marco C, Ríos-Marco P, Jiménez-López JM, Segovia JL, Carrasco MP. Marco C, et al. Anticancer Agents Med Chem. 2014 May;14(4):545-58. doi: 10.2174/1871520614666140309224707. Anticancer Agents Med Chem. 2014. PMID: 24628237 Review.
807 results